Search Results for "manifestation"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
ILLUMINATE Clinical Trial Program Overview
This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.
This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.
ATTR Screening and Carrier
ATTR Screening and Carrier
ATTR Screening and Carrier
Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
Musculoskeletal Manifestations Associated with ATTR Amyloidosis
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
ATTR symptoms and manifestations early indicators
This deck highlights early indicators of ATTR and systemic manifestations.
This deck highlights early indicators of ATTR and systemic manifestations.
Symptoms and Disease Burden of ATTR
Title: Symptoms and Disease Burden of ATTR
External description: This slide deck provides an overview of the symptoms and disease burden of ATTR.
Title: Symptoms and Disease Burden of ATTR External description: This slide deck provides an overview of the symptoms and disease burden of ATTR.
Explore ATTR-CM
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
Diagnosis of PH1 in CKD or Dialysis Patients
This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.
This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.
Understanding AHP Infographic
This infographic about AHP describes the types of the disease, including AIP, pathophysiology, clinical presentation of acute and chronic symptoms, epidemiology, and diagnosis
This infographic about AHP describes the types of the disease, including AIP, pathophysiology, clinical presentation of acute and chronic symptoms, epidemiology, and diagnosis
